Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib

Study Number
4486825
Phase
I/II
Age Group
Adult
Principal Investigator
Eunice Wang
Purpose

To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.

Check your eligibility for this trial
Check now
Full Title

Phase 1b/2 study of decitabine and venetoclax in combination with the targeted mutant IDH1 inhibitor olutasidenib

ClinicalTrials.Gov ID
NCT06445959

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.